TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19656277

Group type: EXPERIMENTAL
Intervention: Partial sleep curtailment (4 hours of sleep)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control condition (9 hours of sleep)
Number of subjects: 22
Study: 18353666

Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg i.v.
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: DHB 1.25 mg i.v.
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 83
Study: 15809387

Group type: EXPERIMENTAL
Intervention: Modified consent form alone (standard form modified to meet federal guidelines for readability and processability)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Modified consent form with verbal disclosure
Number of subjects: 305

Group type: COMPARATOR
Intervention: Standard consent form alone
Number of subjects: 305

Group type: COMPARATOR
Intervention: Standard consent form with verbal disclosure
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Modified consent form
Number of subjects: 305
Study: 12095953

Group type: EXPERIMENTAL
Intervention: Mediterranean diet intervention (n=58); weekly cooking course for 1 year, trained by professional chefs in the use of natural ingredients.
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (n=55); advised to increase consumption of fruits and vegetables as recommended by WHO.
Number of subjects: 115

Group type: COMPARATOR
Intervention: Both groups (intervention and control).
Number of subjects: 115
Study: 11106139

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 2075

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2075
Study: 8780999

Group type: EXPERIMENTAL
Intervention: Brief physician-based counseling (3 to 5 min)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Activity monitor (subsample of intervention participants)
Number of subjects: 255
Study: 1858989

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 22
Study: 6657201

Group type: EXPERIMENTAL
Intervention: Conjunctival transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormonal therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ascorbate or citrate (orthomolecular therapy)
Number of subjects: 0
Study: 31648008

Group type: EXPERIMENTAL
Intervention: 1SET (one set of muscle power training)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 3SET (three sets of muscle power training)
Number of subjects: 26
Study: 29304757

Group type: EXPERIMENTAL
Intervention: 5-day modified dot probe task as ABM training
Number of subjects: 77

Group type: COMPARATOR
Intervention: 5-day classic dot probe task as placebo
Number of subjects: 77

Group type: COMPARATOR
Intervention: Waiting list group (no intervention)
Number of subjects: 77
Study: 26751262

Group type: EXPERIMENTAL
Intervention: Low-salicylate diet
Number of subjects: 30
Study: 24754529

Group type: EXPERIMENTAL
Intervention: MAL-PDT
Number of subjects: 44

Group type: COMPARATOR
Intervention: IMIQ 5%
Number of subjects: 44
Study: 22624290

Group type: EXPERIMENTAL
Intervention: Predictive compensation strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Head movement frequency
Number of subjects: 0
Study: 20974319

Group type: EXPERIMENTAL
Intervention: Esreboxetine
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 18412236

Group type: EXPERIMENTAL
Intervention: NexStent plus FilterWire EX/EZ Emboli Protection System
Number of subjects: 454
Study: 16213057

Group type: EXPERIMENTAL
Intervention: Extended release tablets containing felodipine under fed conditions
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Extended release tablets containing felodipine under fasting conditions
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Extended release tablets containing felodipine
Number of subjects: 6
Study: 11845940

Group type: EXPERIMENTAL
Intervention: Multimedia health education intervention
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Control group (baseline)
Number of subjects: 1197
Study: 9952138

Group type: EXPERIMENTAL
Intervention: 4 mg intravenous ondansetron (prophylaxis)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Symptomatic treatment with 1 mg intravenous ondansetron (if necessary)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Prophylaxis in female patients with a history of motion sickness or PONV undergoing highly emetogenic procedures
Number of subjects: 575

Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 575
Study: 7573905

Group type: EXPERIMENTAL
Intervention: Pentazocine 0.40 mg/kg bw and midazolam 0.075 mg/kg bw i.v. (test group P/M)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg/kg bw and midazolam 0.075 mg/kg bw i.v. (test group K25/M)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg bw and midazolam 0.075 mg/kg bw i.v. (test group K50/M)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Local anaesthesia (LA), articaine 4% plus epinephrine 1:200,000 (control group)
Number of subjects: 140
Study: 2248758

Group type: EXPERIMENTAL
Intervention: Sauna bathing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no sauna bathing)
Number of subjects: 50
Study: 6961763

Group type: EXPERIMENTAL
Intervention: Labetalol (mean daily dose 636 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Propranolol (mean dose 276 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11
Study: 31512828

Group type: EXPERIMENTAL
Intervention: 17% EDTA irrigation for different time lengths (1 min, 3 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 60
Study: 27612922

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (4 mg), PRN regimen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dexamethasone intravitreal implant (Ozurdex), single injection
Number of subjects: 30
Study: 24633245

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid fat graft myringoplasty (HAFGM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Modified fat graft myringoplasty (M-FGM)
Number of subjects: 24
Study: 23800946

Group type: EXPERIMENTAL
Intervention: l-menthol
Number of subjects: 83

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 83
Study: 23042771

Group type: EXPERIMENTAL
Intervention: Low-dose thoracic computed tomography (performed in the first and sixth years)
Number of subjects: 17500

Group type: COMPARATOR
Intervention: Chest roentgenography (performed in the first year)
Number of subjects: 17500
Study: 19204856

Group type: EXPERIMENTAL
Intervention: Self-referring ads
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other-referring ads
Number of subjects: 0
Study: 21693030

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg/day from cycle day 1 to 9
Number of subjects: 214

Group type: COMPARATOR
Intervention: Clomiphene citrate 100 mg/day from cycle day 3 to 7
Number of subjects: 214
Study: 16191116

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation, 4-mm tip, n = 15
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cryoablation (CryoCor, San Diego, CA, USA), n = 15
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both RF ablation and cryoablation
Number of subjects: 30
Study: 12097808

Group type: EXPERIMENTAL
Intervention: Acute moderate alcohol consumption
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10416139

Group type: EXPERIMENTAL
Intervention: Saline infusion sonography (SIS)
Number of subjects: 275
Study: 7478121

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 70
Study: 2105548

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 11
Study: 6106740

Group type: EXPERIMENTAL
Intervention: Fresh expressed breast-milk during the day and milk formula at night
Number of subjects: 70

Group type: COMPARATOR
Intervention: Milk formula only
Number of subjects: 70
Study: 28801033

Group type: EXPERIMENTAL
Intervention: Exercise intervention targeting lower limb strength and balance, tailored and progressive with seven recommended contacts over six months.
Number of subjects: 0
Study: 27755474

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 107
Study: 24884651

Group type: EXPERIMENTAL
Intervention: Increased therapy time (from 8.6 to at least 13 hours a week) with interventions focused on strength, mobility, and balance.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy according to the Dutch stroke Guideline.
Number of subjects: 0
Study: 23311172

Group type: EXPERIMENTAL
Intervention: Compound granule prescription of thunberg fritillary bulb
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 20946685

Group type: EXPERIMENTAL
Intervention: WBV with flexed knees (FK)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: WBV with locked knees (LK)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham WBV with flexed knees (CON)
Number of subjects: 19
Study: 18674989

Group type: EXPERIMENTAL
Intervention: CLBP group lifting differently than controls (n=46)
Number of subjects: 81

Group type: COMPARATOR
Intervention: CLBP group lifting similarly to controls (n=35)
Number of subjects: 81
Study: 15990070

Group type: EXPERIMENTAL
Intervention: Five different sets of inertial parameters
Number of subjects: 10
Study: 12461391

Group type: EXPERIMENTAL
Intervention: OP‐1 Implant
Number of subjects: 20

Group type: COMPARATOR
Intervention: Autograft bone
Number of subjects: 20
Study: 10337884

Group type: EXPERIMENTAL
Intervention: Ice pack applied for 10 minutes before catheter insertion
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no ice pretreatment)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Preference for method (ice pretreatment vs no pretreatment)
Number of subjects: 28
Study: 7795920

Group type: EXPERIMENTAL
Intervention: SCAN/DSM-III-R assessment
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: GAF score assessment
Number of subjects: 706
Study: 2027058

Group type: EXPERIMENTAL
Intervention: Tricalcium phosphate, plaster of paris, and doxycycline composite graft
Number of subjects: 15

Group type: COMPARATOR
Intervention: Surgical debridement alone (Control)
Number of subjects: 15
Study: 7387242

Group type: EXPERIMENTAL
Intervention: SciMed membrane oxygenator
Number of subjects: 60

Group type: COMPARATOR
Intervention: Harvey bubble oxygenator
Number of subjects: 60
Study: 31192246

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and folinic acid (FUFA)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Folfiri
Number of subjects: 269
Study: 29925889

Group type: EXPERIMENTAL
Intervention: Inhibitory theta-burst stimulation (TBS) applied to the right inferolateral prefrontal cortex (ilPFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham or excitatory TMS
Number of subjects: 0
Study: 26800571

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Sleep duration variability
Number of subjects: 806
Study: 25007676

Group type: EXPERIMENTAL
Intervention: Conventional laryngeal microsurgery
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 2 W CO2 laser
Number of subjects: 200

Group type: COMPARATOR
Intervention: 6 W CO2 laser
Number of subjects: 200
Study: 22544644

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 100 mg (40 μCi) [¹⁴C]‐lacosamide over 60 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral administration of 100 mg (40 μCi) [¹⁴C]‐lacosamide as an oral solution
Number of subjects: 10
Study: 20378999

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Combination therapy (half-dose trandolapril plus half-dose valsartan)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control (Trandolapril)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control (Valsartan)
Number of subjects: 195
Study: 17977544

Group type: EXPERIMENTAL
Intervention: Danazol prophylaxis
Number of subjects: 32

Group type: COMPARATOR
Intervention: No danazol treatment (Control)
Number of subjects: 32
Study: 15976785

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 78
Study: 11773543

Group type: EXPERIMENTAL
Intervention: Heliox therapy (70% helium and 30% oxygen)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Heliox therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (supportive care and nebulized epinephrine)
Number of subjects: 38
Study: 9696169

Group type: EXPERIMENTAL
Intervention: Ketorolac (10 mg every 4 to 6 h as needed, up to four daily doses)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Acetaminophen-codeine (600 mg-60 mg every 4 to 6 h as needed, up to six daily doses)
Number of subjects: 123
Study: 8134481

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 100

Group type: COMPARATOR
Intervention: Temazepam
Number of subjects: 100
Study: 2768601

Group type: EXPERIMENTAL
Intervention: Pre-designed educational programme providing complex role experiences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active exposure to and assumption of variegated roles in different settings
Number of subjects: 0
Study: 47538

Group type: EXPERIMENTAL
Intervention: Leucocyte-poor blood (L.P.B.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Whole blood and ordinary packed red blood-cells (R.B.C.)
Number of subjects: 40
Study: 31423649

Group type: EXPERIMENTAL
Intervention: 60 minutes delivery room skin-to-skin contact (DR-SSC)
Number of subjects: 88

Group type: COMPARATOR
Intervention: 5 minutes visual contact (VC)
Number of subjects: 88
Study: 31345462

Group type: EXPERIMENTAL
Intervention: Adjunctive sertraline (400 mg/day for 2 weeks, then 200 mg/day for 12 weeks, tapered over 3 weeks)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo (standard therapy with 7-14 days of intravenous amphotericin B and oral fluconazole)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Adjunctive sertraline
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study: 28906040

Group type: EXPERIMENTAL
Intervention: lokivetmab (1–3.3 mg/kg, monthly injectable)
Number of subjects: 274

Group type: COMPARATOR
Intervention: ciclosporin (5 mg/kg/once daily)
Number of subjects: 274
Study: 25659998

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 792
Study: 23896824

Group type: EXPERIMENTAL
Intervention: TAC/AZA/ST
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: TAC/MMF/ST
Number of subjects: 77
Study: 22734234

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (10 mg/d) and bicyclol (25 mg, tid.)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Adefovir dipivoxil (10 mg/d)
Number of subjects: 96
Study: 19259899

Group type: EXPERIMENTAL
Intervention: Fetal pulse oximetry
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Computerised CTG analysis
Number of subjects: 5
Study: 17115982

Group type: EXPERIMENTAL
Intervention: Acupuncture (8 to 15 sessions)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Metoprolol (100 to 200 mg daily)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 114

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 114
Study: 15095933

Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel (Plavix) combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin and warfarin combination therapy
Number of subjects: 0
Study: 11134431

Group type: EXPERIMENTAL
Intervention: rhGM-CSF (5 microgram/kg/day) for 7 consecutive days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Number of subjects: 60
Study: 9502626

Group type: EXPERIMENTAL
Intervention: Streptokinase and subcutaneous heparin treatment
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Intravenous heparin
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Baseline levels of F1.2
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Values 12 h after enrollment
Number of subjects: 292
Study: 8044945

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/d)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 2656331

Group type: EXPERIMENTAL
Intervention: PSK immunotherapy (n = 21)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 38
Study: 28128726

Group type: EXPERIMENTAL
Intervention: Ferric citrate
Number of subjects: 441

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 441
Study: 31845832

Group type: EXPERIMENTAL
Intervention: Post-orthodontic aligned teeth
Number of subjects: 232

Group type: COMPARATOR
Intervention: Pre-orthodontic crowded teeth
Number of subjects: 232

Group type: COMPARATOR
Intervention: Pre-orthodontic missing teeth
Number of subjects: 232
Study: 31220283

Group type: EXPERIMENTAL
Intervention: Home-based interval walking 150 min/wk for 12 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 39
Study: 27657997

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200 mg daily for 12 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 26151785

Group type: EXPERIMENTAL
Intervention: Efinaconazole topical solution, 10%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 24143092

Group type: EXPERIMENTAL
Intervention: Advanced medications
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional medications
Number of subjects: 80
Study: 21643784

Group type: EXPERIMENTAL
Intervention: Pharmacy-led education and self-management programme
Number of subjects: 127

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 127
Study: 20628481

Group type: EXPERIMENTAL
Intervention: Parent postcard
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Parent print messages
Number of subjects: 684

Group type: COMPARATOR
Intervention: Adolescent flyer
Number of subjects: 684
Study: 16261567

Group type: EXPERIMENTAL
Intervention: Guanfacine (noradrenergic agonist)
Number of subjects: 0
Study: 12060475

Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Phototrichogram (CE-PTG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (5 subjects)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Scalp Coverage Scoring (SCS) method
Number of subjects: 21
Study: 10825857

Group type: EXPERIMENTAL
Intervention: Colgate Platinum Whitening Toothpaste with Fluoride
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Aquafresh Advanced Whitening Toothpaste with Fluoride
Number of subjects: 149

Group type: COMPARATOR
Intervention: Crest Regular Fluoride Toothpaste
Number of subjects: 149
Study: 7480531

Group type: EXPERIMENTAL
Intervention: lorazepam
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: alprazolam
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: amitriptyline
Number of subjects: 342

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: benzodiazepines (lorazepam and alprazolam)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: all treatment groups
Number of subjects: 342
Study: 2401176

Group type: EXPERIMENTAL
Intervention: Surgery plus chemotherapy
Number of subjects: 170

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Radical operation plus chemotherapy
Number of subjects: 170

Group type: COMPARATOR
Intervention: Radical operation alone
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Radical operation plus chemotherapy in Stage II and III lesions
Number of subjects: 170

Group type: COMPARATOR
Intervention: Radical operation alone in Stage II and III lesions
Number of subjects: 170
Study: 6772449

Group type: EXPERIMENTAL
Intervention: Topical slow-release nitroglycerin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral slow-release nitroglycerin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6364030

Group type: EXPERIMENTAL
Intervention: 0.2 mg I.V. indomethacin just after diagnosis
Number of subjects: 24

Group type: COMPARATOR
Intervention: Left untreated for 48 hours
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: I.V. or oral indomethacin (ad libitum) after 48 hours
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: I.V. indomethacin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Surgical closure
Number of subjects: 24
Study: 31430578

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (EST)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Platelet rich plasma (PRP)
Number of subjects: 100
Study: 29848009

Group type: EXPERIMENTAL
Intervention: Contextualised physical activity intervention
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (baseline to 12 weeks)
Number of subjects: 21
Study: 26643530

Group type: EXPERIMENTAL
Intervention: Antimicrobial hand towels
Number of subjects: 369

Group type: COMPARATOR
Intervention: Control (education alone)
Number of subjects: 369
Study: 25157725

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (3000 IU/kg)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495
Study: 22818065

Group type: EXPERIMENTAL
Intervention: β(1)-AR blockade (Toprol-XL)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 20599192

Group type: EXPERIMENTAL
Intervention: Learning in dyadic minimal social situation over 200 rounds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Learning in multiplayer groups with strategic interaction and communication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monte Carlo simulation of decision-making in minimal social situations
Number of subjects: 0
Study: 17507741

Group type: EXPERIMENTAL
Intervention: Caffeinated sports drink (CAF+CE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Carbohydrate-electrolyte (CE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 16